Should I buy or sell Chimerix stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMRX shares. View CMRX analyst ratings or view top-rated stocks .

What is Chimerix's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month target prices for Chimerix's shares. Their CMRX share price targets range from $6.00 to $11.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 805.6% from the stock's current price. View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts .

How have CMRX shares performed in 2024?

Chimerix's stock was trading at $0.9625 on January 1st, 2024. Since then, CMRX shares have decreased by 8.2% and is now trading at $0.8834. View the best growth stocks for 2024 here .

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CMRX earnings forecast .

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. Chimerix had a negative net margin of 25,337.96% and a negative trailing twelve-month return on equity of 37.93%.

What other stocks do shareholders of Chimerix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT) , Immunomedics (IMMU) , Synergy Pharmaceuticals (SGYP) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , Inovio Pharmaceuticals (INO) , OPKO Health (OPK) , VBI Vaccines (VBIV) and TherapeuticsMD (TXMD) .

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CMRX

Chimerix (CMRX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CMRX Stock Alerts

$0.88

-0.05 (-5.25%)

(As of 03:27 PM ET)

Compare

Today's Range: $0.88
▼
$0.94
50-Day Range: $0.90
▼
$1.26
52-Week Range: $0.88
▼
$1.57

Volume: 360,652 shs
Average Volume: 403,038 shs
Market Capitalization: $78.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Chimerix alerts:

Chimerix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 805.6% Upside
$8.00 Price Target
Short Interest: Healthy
1.56% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.49
Upright™ Environmental Score
News Sentiment: 0.51
Based on 3 Articles This Week
Insider Trading: Selling Shares
$6,598 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.77) to ($0.95) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.11 out of 5 stars

Medical Sector

155th out of 918 stocks

Pharmaceutical Preparations Industry

56th out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
Chimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Chimerix has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.56% of the float of Chimerix has been sold short.
Short Interest Ratio / Days to Cover
Chimerix has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Chimerix has recently decreased by 1.59%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Chimerix does not currently pay a dividend.
Dividend Growth
Chimerix does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Chimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for Chimerix is -2.49.

2.0

News and Social Media Coverage

News Sentiment
Chimerix has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Chimerix this week, compared to 1 article on an average week.
Search Interest
Only 7 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Chimerix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chimerix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,598.00 in company stock.
Percentage Held by Insiders
Only 10.00% of the stock of Chimerix is held by insiders.
Percentage Held by Institutions
45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Chimerix are expected to decrease in the coming year, from ($0.77) to ($0.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chimerix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chimerix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Chimerix has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Chimerix Stock (NASDAQ:CMRX)

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

CMRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CMRX Stock News Headlines

April 16, 2024 | globenewswire.com

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 16, 2024 | americanbankingnews.com

Chimerix (NASDAQ:CMRX) Stock Price Crosses Below 200 Day Moving Average of $1.00

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 15, 2024 | finance.yahoo.com

We Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth Carefully

March 16, 2024 | finance.yahoo.com

CMRX Apr 2024 2.000 call

March 16, 2024 | finance.yahoo.com

CMRX Apr 2024 1.000 put

March 5, 2024 | finance.yahoo.com

Chimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 2, 2024 | seekingalpha.com

Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 1, 2024 | seekingalpha.com

Chimerix: Tackling A Strong Unmet Need With Promising Data

March 1, 2024 | finance.yahoo.com

Chimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call Transcript

February 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Chimerix Amid Progress in Dordaviprone’s Phase III Study and Strong Financial Outlook

February 29, 2024 | finanznachrichten.de

Chimerix, Inc.: Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

February 29, 2024 | finance.yahoo.com

Chimerix Inc Reports Fourth Quarter and Full-Year 2023 Financial Results

February 29, 2024 | globenewswire.com

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

February 28, 2024 | benzinga.com

Preview: Chimerix's Earnings

February 28, 2024 | markets.businessinsider.com

Chimerix is about to announce its earnings — here's what Wall Street expects

February 27, 2024 | finance.yahoo.com

Chimerix to Present at TD Cowen 44th Annual Health Care Conference

February 22, 2024 | finance.yahoo.com

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

February 22, 2024 | globenewswire.com

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

February 18, 2024 | finance.yahoo.com

Chimerix, Inc. (NASDAQ:CMRX) surges 24%; individual investors who own 43% shares profited along with institutions

January 9, 2024 | msn.com

Lightning Could Strike Twice for Biotech Penny Stock Chimerix (NASDAQ:CMRX)

December 29, 2023 | finance.yahoo.com

Chimerix Appoints Lisa Decker to Board of Directors

December 14, 2023 | finance.yahoo.com

Positive Signs As Multiple Insiders Buy Chimerix Stock

December 4, 2023 | marketwatch.com

Chimerix Names Michelle LaSpaluto to Chief Financial Officer

December 4, 2023 | msn.com

Chimerix promotes Michelle Laspaluto to CFO

December 4, 2023 | markets.businessinsider.com

Chimerix Appoints Michelle LaSpaluto As CFO

See More Headlines

Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CMRX
CUSIP: N/A
CIK: 1117480
Web: www.chimerix.com
Phone: (919) 806-1074
Fax: 919-806-1146
Employees: 72
Year Founded: 2000

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $11.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +777.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-82,100,000.00
Net Margins: -25,337.96%
Pretax Margin: -25,337.96%
Return on Equity: -37.93%
Return on Assets: -35.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.25
Quick Ratio: 10.25

Sales & Book Value

Annual Sales: $320,000.00
Price / Sales: 254.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.17 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 89,210,000
Free Float: 80,289,000
Market Cap: $81.38 million
Optionable: Optionable
Beta: 1.15

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Michael T. Andriole M.B.A. (Age 51)
CEO, President & Director
Comp: $592.95k
Dr. Allen S. Melemed M.B.A. (Age 60)
M.D., Chief Medical Officer
Comp: $605.29k
Ms. Michelle LaSpaluto (Age 49)
Chief Financial Officer
Mr. Thomas J. Riga (Age 48)
Chief Operating & Commercial Officer
Mr. David Jakeman CPA (Age 46)
VP of Accounting & Finance
Dr. Joshua E. Allen Ph.D.
Chief Technology Officer
Dr. Michael A. Alrutz J.D. (Age 54)
Ph.D., Senior VP, General Counsel & Corporate Secretary
Comp: $619.5k
Dr. Roy W. Ware MBA
Ph.D., Chief Manufacturing Technology Officer
Dr. Pablo Lee M.D.
Head of Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings or view top-rated stocks.
What is Chimerix's stock price target for 2024?: 3 Wall Street research analysts have issued twelve-month target prices for Chimerix's shares. Their CMRX share price targets range from $6.00 to $11.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 805.6% from the stock's current price.
View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts.
How have CMRX shares performed in 2024?: Chimerix's stock was trading at $0.9625 on January 1st, 2024. Since then, CMRX shares have decreased by 8.2% and is now trading at $0.8834.
View the best growth stocks for 2024 here.
When is Chimerix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CMRX earnings forecast.

How were Chimerix's earnings last quarter?: Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. Chimerix had a negative net margin of 25,337.96% and a negative trailing twelve-month return on equity of 37.93%.
What other stocks do shareholders of Chimerix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD).
How do I buy shares of Chimerix?: Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial